Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

TARGET–NASH: A 5-year Longitudinal Observational Study of Patients with Non-Alcoholic Fatty Liver or Non-Alcoholic Steatohepatitis

Clinical Trial Details

This is an observational study. This study is for men and women who have nonalcoholic fatty liver (NAFL), which is storage of fat in the liver, or NASH (nonalcoholic steatohepatitis) which is a form of NAFL liver disease that includes irritation or inflammation of the liver due to fat. 

The purpose of this study to observe any treatment for NAFL/NASH in a large number of people in a “real life” setting. Researchers are interested in observing how these lifestyle changes, counseling, or other treatments work in patients who are treated by their doctors in routine practice. Any treatments for NAFL/NASH will be chosen by the participant and the study doctor. No specific treatments will be prescribed just by participating in this study. 

If an individual agrees to participate in this study, their past (up to 3 years before) and future (up to 5 years) medical records will be collected. 

In addition, participants will have the opportunity to participate in optional portions in this study: 

  • Optional blood sample collection 
  • Optional questionnaire 

Participation in the study will last for up to 5 years. 

Participants will be reimbursed for their time. 

Key Eligibility: 

Men and women who are 18 and over
Have been diagnosed with NASH or NAFL
Detailed eligibility reviewed when contacting the study team

Study contact by location

Upper East Side - Manhattan


GI/ Hepatology
(646) 962-4040

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group